|本期目录/Table of Contents|

[1]李长建,王会青,王玉华,等.NCAPG和CDK1促进膀胱癌细胞增殖[J].天津医科大学学报,2024,30(06):491-496，502.[doi:10.20135/j.issn.1006-8147.2024.06.0491]
　LI Changjian,WANG Huiqing,WANG Yuhua,et al.NCAPG and CDK1 promote bladder cancer cell proliferation[J].Journal of Tianjin Medical University,2024,30(06):491-496，502.[doi:10.20135/j.issn.1006-8147.2024.06.0491]
点击复制

NCAPG和CDK1促进膀胱癌细胞增殖(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
30卷
期数:
2024年06期
页码:
491-496，502
栏目:
肿瘤疾病专题
出版日期:
2024-11-20

文章信息/Info

Title:
NCAPG and CDK1 promote bladder cancer cell proliferation
文章编号:
1006-8147(2024)06-0491-07
作者:
李长建1; 王会青1; 王玉华1; 王亚林1; 窦启锋2
（1.新乡医学院第三附属医院泌尿外科，新乡453000；2.新乡医学院第一附属医院泌尿外科，卫辉 453100）
Author(s):
LI Changjian1; WANG Huiqing1; WANG Yuhua1; WANG Yalin1; DOU Qifeng2
（1.Department of Urology，The Third Affiliated Hospital of Xinxiang Medical College，Xinxiang 453000，China；2.Department of Urology，The First Affiliated Hospital of Xinxiang Medical College，Weihui 453100，China）
关键词:
NCAPG; CDK1; 膀胱癌; 治疗靶点; 增殖
Keywords:
NCAPG; CDK1; bladder cancer; therapeutic target; proliferation
分类号:
R737.14
DOI:
10.20135/j.issn.1006-8147.2024.06.0491
文献标志码:
A
摘要:
目的：探讨非SMC凝缩蛋白Ⅰ复合物亚基G（NCAPG）和细胞周期蛋白依赖性激酶1（CDK1）在膀胱癌细胞和膀胱癌组织中的作用。方法：通过生物信息学分析，比较NCAPG和CDK1在膀胱癌和正常组织中的表达。之后再对NCAPG和CDK1进行相关性分析，对新乡医学院第一和第三附属医院泌尿外科72例膀胱癌患者术后病理组织进行免疫组化染色，进一步验证其相关性。选取膀胱癌细胞T24和5637，将其分为两组，未敲低NCAPG的为对照组，转染shRNA敲低NCAPG的为shRNA组，qRT-PCR和Western印迹验证敲低效果，通过克隆形成和CCK-8实验检测其对膀胱癌细胞增殖的影响，并应用细胞周期实验，检测其对膀胱癌细胞周期的影响。结果：与正常膀胱组织相比，NCAPG和CDK1在膀胱癌组织中表达上调。NCAPG和CDK1免疫组化染色的相关性分析进一步证实了NCAPG与CDK1相关 （χ2=10.286，P<0.001）。通过结合临床资料进一步发现，NCAPG的表达与肿瘤大小密切相关（χ2=6.675，P=0.010）。qRT-PCR和Western 印迹结果显示，NCAPG shRNA明显抑制了NCAPG mRNA（t=5.422、5.238，均P<0.05）及蛋白的表达（t=4.756、4.122，均P<0.05）。同时CCK-8实验和克隆形成实验发现，敲低NCAPG会抑制膀胱癌细胞的增殖（t=5.886、4.147、3.102、3.745，均P<0.05）。细胞周期结果发现，敲低NCAPG后阻滞了膀胱癌细胞的G2/M期（t=2.566、2.926，均P<0.05）。结论：NCAPG和CDK1在膀胱癌细胞中高表达，会促进膀胱癌细胞的增殖。
Abstract:
Objective：To investigate the role of the non-SMC condensin Ⅰ complex subunit G （NCAPG） and cyclin dependent kinase 1 （CDK1） in bladder cancer cells and bladder cancer tissues. Methods：Bioinformatics analysis was used to compare the expression of NCAPG and CDK1 in bladder cancer and normal tissues. The correlation between NCAPG and CDK1 was analyzed，and immunohistochemical staining was performed on the pathological tissues of 72 patients with bladder cancer after surgery in our hospital to further verify their correlation. Bladder cancer cells T24 and 5637 were selected and divided into two groups. The control group was the one that did not knock down NCAPG，and the shRNA group was the one that transfected shRNA to knock down NCAPG. QRT-PCR and Western blotting were used to verify the knockdown effect，clone formation and CCK8 assay were used to detect the effect of NCAPG on bladder cancer cell proliferation，and the cell cycle experiment was used to detect the effect on the cell cycle of bladder cancer. Results：NCAPG and CDK1 were up-regulated in bladder cancer tissues compared with normal bladder tissues. And the correlation analysis of NCAPG and CDK1 immunohistochemical staining further confirmed that NCAPG was related to CDK1（χ2=10.286，P<0.001）. Combined with clinical data，it was further found that the expression of NCAPG was closely related to tumor size（χ2=6.675， P=0.010）. QRT-PCR and Western blotting results showed that NCAPG shRNA significantly inhibited the expression of NCAPG mRNA （t=5.422，5.238，both P<0.05） and protein （t=4.756，4.122，both P<0.05）. Meanwhile，knockdown of NCAPG inhibited the proliferation of bladder cancer cells according to colony formation and CCK8 assay （t=5.886，4.147，3.102，3.745，all P<0.05）. Cell cycle results showed that NCAPG knockdown blocked the G2/M phase of bladder cancer cells （t=2.566，2.926，both P<0.05）. Conclusion：NCAPG and CDK1 are highly expressed in bladder cancer cells and can promote the proliferation of bladder cancer cells.

参考文献/References:

[1] RANTI D，BIEBER C，WANG Y S，et al. Natural killer cells：unlocking new treatments for bladder cancer[J]. Trends Cancer，2022，8（8）：698-710.
[2] SIEGEL R L，GIAQUINTO A N，JEMAL A. Cancer Statistics，2024[J].CA Cancer J Clin，2024，74（1）：12-49.
[3] GRAYSON M. Bladder cancer[J]. Nature，2017，551（7679）：S33.
[4] LI S，WANG J，ZHANG Z，et al. Establishment and validation of nomograms to predict the overall survival and cancer-specific survival for non-metastatic bladder cancer patients：a large population-based cohort study and external validation[J]. Medicine （Baltimore），2024，103（11）：e37492.
[5] CAI X，GAO J，SHI C，et al.The role of NCAPG in various of tumors[J]. Biomed Pharmacother，2022，155：113635.
[6] TANG F，YU H，WANG X，et al. NCAPG promotes tumorigenesis of bladder cancer through NF-κB signaling pathway[J]. Biochem Biophys Res Commun，2022，622：101-107.
[7] MICHOWSKI W，CHICK J M，CHU C，et al. Cdk1 controls global epigenetic landscape in embryonic stem cells[J]. Mol Cell，2020，78（3）：459-476.
[8] CHEN J，WANG W，LI S，et al. RNA-seq reveals role of cell-cycle regulating genes in the pathogenicity of a field very virulent infectious bursal disease virus[J]. Front Vet Sci，2024，11：1334586.
[9] XIE B，WANG S，JIANG N，et al. Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance[J]. Cancer Lett，2019，443：56-66.
[10] LI M，HE F，ZHANG Z，et al. CDK1 serves as a potential prognostic biomarker and target for lung cancer[J]. J Int Med Res，2020，48（2）：300060519897508.
[11] HENRICH L M，GREIMELMAIER K，WESSOLLY M，et al. The impact of cancer-associated fibroblasts on the biology and progression of colorectal carcinomas[J]. Genes （Basel），2024，15（2）：209.
[12] GAO J，LU Q，ZHONG J，et al. Identification and validation of an H2AZ1-based index model：a novel prognostic tool for hepatocellular carcinoma[J]. Aging （Albany NY），2024，16（3）：2542-2562.
[13] CAI X，GAO J，SHI C，et al. The role of NCAPG in various of tumors[J]. Biomed Pharmacother，2022，155：113635.
[14] WU Y，LIN Y，PAN J，et al. NCAPG promotes the progression of lung adenocarcinoma via the TGF-β signaling pathway[J]. Cancer Cell Int，2021，21（1）：443.
[15] GONG C，AI J，FAN Y，et al. NCAPG promotes the proliferation of hepatocellular carcinoma through PI3K/AKT signaling[J]. Onco Targets Ther，2019，12：8537-8552.
[16] ZHENG G，HAN T，HU X，et al. NCAPG Promotes tumor progression and modulates immune cell infiltration in glioma[J]. Front Oncol，2022，12：770628.
[17] XIE B，WANG S，JIANG N，et al. Cyclin B1/CDK1-regulated mitochondrial bioenergetics in cell cycle progression and tumor resistance[J]. Cancer Lett，2019，443：56-66.
[18] TANG F，YU H，WANG X，et al. NCAPG promotes tumorigenesis of bladder cancer through NF-κB signaling pathway[J]. Biochem Biophys Res Commun，2022，622：101-107.
[19] SOFI S，MEHRAJ U，QAYOOM H，et al. Targeting cyclin-dependent kinase 1 （CDK1） in cancer：molecular docking and dynamic simulations of potential CDK1 inhibitors[J]. Med Oncol，2022，39（9）：133.
[20] WANG Q，BODE A M，ZHANG T. Targeting CDK1 in cancer：mechanisms and implications[J]. NPJ Precis Oncol，2023，7（1）：58.
[21] HUANG S，XIAO J，WU J，et al. Tizoxanide promotes apoptosis in glioblastoma by inhibiting CDK1 activity[J]. Front Pharmacol，2022，13：895573.
[22] ZHOU L，MU D，CHEN Y. LINC00958 targets miR-145-3p/CDK1 axis to aggravate the malignancy of colon cancer[J]. Ann Clin Lab Sci，2022，52（5）：695-706.

相似文献/References:

备注/Memo

备注/Memo:
作者简介 李长建（1983-），男，副主任医师，硕士，研究方向：泌尿系统肿瘤的临床与基础研究；
通信作者：窦启锋，E-mail：douqifeng@ 126.com。
更新日期/Last Update: 2024-11-25